176 related articles for article (PubMed ID: 34614441)
1. Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept.
Cojutti PG; Rinaldi M; Gatti M; Tedeschi S; Viale P; Pea F
Int J Antimicrob Agents; 2021 Nov; 58(5):106445. PubMed ID: 34614441
[TBL] [Abstract][Full Text] [Related]
2. Teicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration.
Peeters O; Ferry T; Ader F; Boibieux A; Braun E; Bouaziz A; Karsenty J; Forestier E; Laurent F; Lustig S; Chidiac C; Valour F;
BMC Infect Dis; 2016 Nov; 16(1):622. PubMed ID: 27809799
[TBL] [Abstract][Full Text] [Related]
3. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
[TBL] [Abstract][Full Text] [Related]
4. [Problems with teicoplanin in the treatment of osteoarticular infections caused by methicillin-resistant S. aureus].
Gómez J; Climent C; Herrero F; Ruano L
Enferm Infecc Microbiol Clin; 1992 Nov; 10(9):567-8. PubMed ID: 1489810
[No Abstract] [Full Text] [Related]
5. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
[TBL] [Abstract][Full Text] [Related]
6. [Prolonged treatment with dalbavancin in prosthetic hip infection by methicillin-resistant Staphylococcus epidermidis].
Trujillano Ruiz A; Mesquida Riera J; Serrano Fabiá MA; Riera Pérez E; Mejía Benard A; Taberner Ferrer MD
Rev Esp Quimioter; 2019 Apr; 32(2):203-204. PubMed ID: 30868837
[No Abstract] [Full Text] [Related]
7. Treatment with dalbavancin in a patient with septic thrombophlebitis of the internal jugular vein due to Staphylococcus aureus after insertion of an implantable cardioverter defibrillator.
Martínez-Sanz J; Gijón de la Santa L; Torralba M
Enferm Infecc Microbiol Clin (Engl Ed); 2018; 36(6):389-390. PubMed ID: 29132942
[No Abstract] [Full Text] [Related]
8. Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.
Almangour TA; Fletcher V; Alessa M; Alhifany AA; Tabb D
Am J Case Rep; 2017 Dec; 18():1315-1319. PubMed ID: 29222405
[TBL] [Abstract][Full Text] [Related]
9. Dalbavancin treatment of prosthetic knee infection due to oxacillin-resistant Staphylococcus epidermidis.
Ramírez Hidalgo M; Jover-Sáenz A; García-González M; Barcenilla-Gaite F
Enferm Infecc Microbiol Clin (Engl Ed); 2018 Feb; 36(2):142-143. PubMed ID: 28600171
[No Abstract] [Full Text] [Related]
10. [Treatment of MRSA infections].
Borde JP; Kern WV
Dtsch Med Wochenschr; 2012 Dec; 137(49):2553-7. PubMed ID: 23143638
[No Abstract] [Full Text] [Related]
11. In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections.
Fernández J; Greenwood-Quaintance KE; Patel R
Diagn Microbiol Infect Dis; 2016 Aug; 85(4):449-51. PubMed ID: 27241369
[TBL] [Abstract][Full Text] [Related]
12. [The comparative costs of vancomycin treatment versus teicoplanin in osteoarticular infection caused by methicillin-resistant staphylococci].
Pham Dang C; Gouin F; Touchais S; Richard C; Potel G
Pathol Biol (Paris); 2001 Sep; 49(7):587-96. PubMed ID: 11642024
[TBL] [Abstract][Full Text] [Related]
13. Dalbavancin combined with linezolid in prosthetic-hip infection.
Carrión Madroñal IM; Sánchez Del Moral R; Abad Zamora JM; Martínez Marcos FJ
Rev Esp Quimioter; 2020 Apr; 33(2):147-148. PubMed ID: 32157859
[No Abstract] [Full Text] [Related]
14. Therapeutic potential of dalbavancin in a rat model of methicillin-resistant Staphylococcus aureus (MRSA)-osteomyelitis.
Silva V; Miranda C; Antão HS; Guimarães J; Prada J; Pires I; Maltez L; Pereira JE; Capelo JL; Igrejas G; Poeta P
Int J Antimicrob Agents; 2020 Jul; 56(1):106021. PubMed ID: 32439480
[TBL] [Abstract][Full Text] [Related]
15. Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for subacute and chronic staphylococcal infections.
Cojutti PG; Gatti M; Punt N; Douša J; Zamparini E; Tedeschi S; Viale P; Pea F
Int J Antimicrob Agents; 2024 Jan; 63(1):107038. PubMed ID: 37981075
[TBL] [Abstract][Full Text] [Related]
16. Three-times weekly teicoplanin as outpatient treatment of chronic osteoarticular infections.
Tascini C; Tagliaferri E; Di Paolo A; Ciofi L; Del Tacca M; Lambelet P; Menichetti F
J Chemother; 2009 Aug; 21(4):421-5. PubMed ID: 19622461
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains.
Citron DM; Tyrrell KL; Goldstein EJ
Diagn Microbiol Infect Dis; 2014 Aug; 79(4):438-40. PubMed ID: 24972854
[TBL] [Abstract][Full Text] [Related]
18. A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections.
Gatti M; Viale P; Cojutti PG; Zamparini E; De Paolis M; Giannella M; Pea F; Tedeschi S
Int J Antimicrob Agents; 2023 May; 61(5):106773. PubMed ID: 36878410
[TBL] [Abstract][Full Text] [Related]
19. Dalbavancin was effective and safe after one year of treatment in a complicated osteoarticular infection caused by methicillin-resistant Staphylococcus aureus.
Matesanz M; Poza A; Iñurrieta A; Fernández-Diaz E; Arroyo M; Domínguez I; Candel FJ
Rev Esp Quimioter; 2021 Aug; 34(4):396-399. PubMed ID: 33956412
[No Abstract] [Full Text] [Related]
20. [Child osteoarticular infections: statements and perspectives].
Cohen R; Grimprel E
Arch Pediatr; 2007 Oct; 14 Suppl 2():S79-80. PubMed ID: 17956822
[No Abstract] [Full Text] [Related]
[Next] [New Search]
